登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 截至挂牌期满，北京产权交易所征集到1家意向受让方。因该意向受让方未在规定期限内完成保证金缴 纳程序，本次股权挂牌转让事项相应终止。 二、本次交易终止对上市公司的影响 本次股权挂牌转让终止不会对公司的正常生产经营及财务状况产生重大影响。 特此公告。 广东汕头超声电子股份有限公司董事会 2026年1月20日 一、交易基本情况及进展 广东汕头超声电子股份有限公司（以下简称"公司"）于2024年10月29日召开第十届董事会第二次会议， 审议通过了《关于公开挂牌转让本公司持有的四川超声印制板有限公司股权的议案》，同意公司通过北 京产权交易所公开挂牌、拍卖转让持有的四川超声印制板有限公司（以下简称"四川超声"）62%股权， 挂牌底价为7,456.29万元。具体内容详见公司于2024年10月30日披露的《广东汕头超声电子股份有限公 司关于公开挂牌转让本公司持有的超声印制板有限公司股权的公告》（公告编号：2024-044）。2024年 12月24日，上述股权在北京产权交易所开始正 ...

Core Viewpoint - Yonghui Supermarket Co., Ltd. has announced its 2025 annual performance forecast, expecting a net loss of 2.14 billion yuan and a net loss of 2.94 billion yuan after deducting non-recurring gains and losses, primarily due to strategic adjustments and store closures [25][26][28]. Group 1: Board Meeting Resolutions - The 10th meeting of the 6th Board of Directors was held on January 19, 2026, with all 9 directors present, and resolutions were passed regarding the execution of related party transactions for 2025 and the plan for 2026 [1][4]. - The independent directors approved the related party transaction proposal [2]. - A proposal to hold the first extraordinary general meeting of shareholders in 2026 was made, scheduled for February 6, 2026 [3][4]. Group 2: Shareholder Meeting Details - The first extraordinary general meeting of shareholders will take place on February 6, 2026, at 1:30 PM at the company's headquarters in Fuzhou [6][7]. - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's online voting system [8][9]. Group 3: 2025 Annual Performance Forecast - The company anticipates a net loss of 2.14 billion yuan for 2025, compared to a net loss of 1.47 billion yuan in the previous year [25][26]. - The expected net loss after deducting non-recurring gains and losses is projected at 2.94 billion yuan, with significant losses attributed to store closures and strategic adjustments [26][27]. - The company has closed 381 stores and restructured 315 stores, incurring substantial costs related to asset write-offs and renovation losses [27]. Group 4: Related Party Transactions - The company plans to engage in related party transactions with a projected amount of 2.9942 billion yuan for 2026, which is deemed necessary for daily operations and will not adversely affect the company's financial status [31][34]. - The board has confirmed that the pricing of related party transactions is fair and based on market conditions, ensuring no harm to the interests of the company or minority shareholders [61][62].

Group 1 - The article discusses the current state of the market, highlighting significant fluctuations in stock prices and investor sentiment [1] - It mentions a recent surge in technology stocks, which have outperformed other sectors, contributing to overall market gains [1] - The report indicates that economic indicators, such as unemployment rates and consumer spending, are showing signs of recovery, which may bolster investor confidence [1] Group 2 - The article provides data on quarterly earnings reports from major companies, revealing a mixed performance across different industries [1] - It notes that companies in the healthcare sector have reported strong growth, while those in the retail sector are facing challenges due to supply chain disruptions [1] - The analysis includes projections for future earnings, suggesting that technology and healthcare will continue to lead the market, while retail may struggle in the short term [1]

Core Viewpoint - Shanghai Beite Technology Group Co., Ltd. has successfully completed the issuance of A-shares to specific investors for the year 2025, raising approximately RMB 300 million, with net proceeds amounting to approximately RMB 293.84 million after deducting issuance costs [4]. Group 1: Issuance Details - The company issued a total of 7,980,845 shares at a price of RMB 37.59 per share, resulting in a total fundraising amount of RMB 299,999,963.55 [4]. - The net proceeds from the fundraising, after deducting issuance expenses of RMB 6,160,704.11, amounted to RMB 293,839,259.44 [4]. - The funds were fully received by January 14, 2026, and the accounting firm Zhonghui CPA has verified the receipt of these funds [4]. Group 2: Fund Management and Supervision - The company has established a special account for the management and storage of the raised funds, in compliance with relevant regulations [5][6]. - A tripartite supervision agreement has been signed between the company, the sponsor China Galaxy Securities, and the bank where the special account is held, ensuring oversight of the fund's usage [6][12]. - The special account for the funds related to the Thailand screw production base project has a balance of RMB 295.80 million as of January 14, 2026, and is strictly designated for this project [7][12]. Group 3: Regulatory Compliance - The company is required to comply with various laws and regulations, including the Securities Issuance and Listing Sponsorship Business Management Measures and the Shanghai Stock Exchange's self-regulatory guidelines [6][12]. - The sponsor has the right to supervise the fund usage and can conduct on-site investigations at least semi-annually [7][12]. - Any significant withdrawals from the special account must be reported to the sponsor, ensuring transparency and accountability in fund management [9][14].

Group 1 - The core project is the B023 cell injection, which has received approval for clinical trials from the National Medical Products Administration (NMPA) for treating inoperable, locally advanced, or metastatic solid tumors that have failed standard treatments [1][2] - B023 is an innovative Class I biological product developed by Shanghai Pharmaceutical Group's subsidiary, with a total research and development investment of approximately 39.26 million RMB [2] - The active component of B023 is invariant natural killer T (iNKT) cells, which can be used universally without causing graft-versus-host disease due to the lack of polymorphism in CD1d among the population [2] Group 2 - As of the announcement date, there are no other drugs with the same indication and type available in the global market [3] - The approval for clinical trials does not significantly impact the company's current operations, and the company will continue to advance the project in accordance with national regulations [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601718 证券简称：际华集团 公告编号：临2026-002 际华集团股份有限公司 第六届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 际华集团股份有限公司（以下简称"公司"）第六届董事会第十六次会议于2026年1月19日召开，会议采 取通讯表决方式进行。应出席会议的董事8人，实际出席会议的董事8人。会议按照会议通知所列议程进 行，会议召集、出席会议董事人数、召开程序等符合有关法律法规和公司章程规定。会议经审议，形成 如下决议： 一、审议通过关于《与关联方共同投资设立合资公司暨关联交易》的议案 表决结果：6票同意、0票弃权、0票反对、2票回避。 本议案在提交董事会审议前已经公司第六届董事会审计与风险管理委员会第十二次会议、第六届董事会 战略与ESG委员会第二次会议、第六届董事会第六次独立董事专门会议审议通过。 在审议该议案时，关联董事陈向东、杨金龙回避了表决。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披 ...

Core Points - The company has received approval from the Shanghai Regulatory Bureau of the National Financial Supervision Administration to issue a new financial license [1] - The company has updated its business scope to include various trust services, asset management, and financial advisory services [1] - The company will proceed with amending its articles of association and business scope as required by law [2] Group 1 - The company has been granted a new financial license, allowing it to operate in multiple areas including trust business and asset management [1] - The specific business scope includes trust services, inherent asset liability business, investment advisory, and overseas wealth management qualifications [1] - The company is located at 1553-1555 Kongjiang Road, Yangpu District, Shanghai [2] Group 2 - The license approval date is May 9, 1991, indicating a long-standing presence in the financial sector [2] - The company will undertake necessary legal procedures to revise its company charter and business scope following the license update [2] - The announcement was made by the board of directors of the company on January 21, 2026 [4]

特此公告。 上海东方证券资产管理有限公司 2026年01月 21日 东方红益恒纯债债券型证券投资基金（以下简称"本基金"）C类基金份额（基金代码：021836）于2026 年01月20日发生大额赎回。为确保基金份额持有人利益不因份额净值的小数点保留精度受到不利影响， 经上海东方证券资产管理有限公司（以下简称"本公司"）与基金托管人协商一致，决定自2026年01月20 日（含）起提高本基金 C类基金份额净值精度至小数点后8位，小数点后第9位四舍五入。本基金C类基 金份额将自大额赎回对基金份额持有人利益不再产生重大影响时起，恢复基金合同约定的净值精度，届 时不再另行公告。 投资者可通过本公司客服电话400-920-0808，或登录本公司网站（https://www.dfham.com/）获取相关信 息。 本基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈利，也不保 证最低收益。请充分了解基金的风险收益特征，审慎做出投资决定。 ...

Core Viewpoint - The company has announced a change in its website and investor contact email to better align with its development needs, effective immediately upon the announcement [1]. Group 1: Company Information - The new company website and investor contact email will be activated, while the old website will continue to be used by the company's wholly-owned subsidiary, Zhengzhou Coal Mining Machinery Group Co., Ltd [1]. - Emails sent to the old investor contact email will be forwarded to the new investor contact email [1]. - Other contact information such as investor phone, fax, and address will remain unchanged [1].

登录新浪财经APP 搜索【信披】查看更多考评等级 一、本次限制性股票回购注销的决策与信息披露 1、2025年11月28日召开了第四届董事会第三十三次会议，审议通过了《关于回购注销部分限制性股票 和注销部分股票期权的议案》。具体内容详见公司2025年11月29日披露的《福建海通发展股份有限公司 关于回购注销部分限制性股票和注销部分股票期权的公告》（公告编号：2025-126）。 2、2025年11月29日，公司在上海证券交易所网站（www.sse.com.cn）及指定媒体发布了《福建海通发 展股份有限公司关于回购注销部分限制性股票通知债权人的公告》（公告编号：2025-127），截至目前 公示期已满45天，公司未收到债权人关于清偿债务或者提供相应担保的要求，也未收到任何债权人对本 次回购事项提出的异议。 二、本次限制性股票回购注销情况 （一）2024年激励计划限制性股票回购注销情况 1、2024年激励计划回购注销限制性股票的原因及依据 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购注销原因：福建海通发展 ...